MARKET

TVRD

TVRD

Tvardi Therapeutics Inc
NASDAQ
1.180
+0.025
+2.16%
After Hours: 1.170 -0.01 -0.85% 19:42 11/13 EST
OPEN
1.160
PREV CLOSE
1.155
HIGH
1.180
LOW
1.080
VOLUME
75.66K
TURNOVER
--
52 WEEK HIGH
5.69
52 WEEK LOW
0.7729
MARKET CAP
15.74M
P/E (TTM)
-0.4250
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Tvardi Therapeutics (TVRD), BioCardia (BCDA)
TipRanks · 16h ago
Tvardi Q3 Loss Widens On Higher Clinical Costs; Liver Cancer Data Due Early Q1 2027
NASDAQ · 23h ago
Tvardi Therapeutics reports Q3 EPS (48c), consensus (57c)
TipRanks · 1d ago
Tvardi Therapeutics Q3 EPS $(0.48) Beats $(0.53) Estimate
Benzinga · 1d ago
Tvardi Therapeutics GAAP EPS of -$0.48 beats by $0.01
Seeking Alpha · 1d ago
*Tvardi Therapeutics 3Q Loss $6.12M >TVRD
Dow Jones · 1d ago
Press Release: Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
Dow Jones · 1d ago
Press Release: Tvardi Therapeutics Announces -2-
Dow Jones · 1d ago
More
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Webull offers Tvardi Therapeutics Inc stock information, including NASDAQ: TVRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVRD stock methods without spending real money on the virtual paper trading platform.